News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cellectis (ALCLS): Genome Engineering & CART Cells: At The Forefront Of Immuno-Oncology


9/2/2014 10:48:23 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK--(BUSINESS WIRE)--Regulatory News:Cellectis (Alternext: ALCLS.PA), a leader in the development of adoptive immunotherapies based on engineered allogeneic CART cells (UCART) will host a R&D/ Analyst Day on Thursday, September 11 at 7:30AM in New York City. Cellectis’ scientists will provide an overview of the Company's therapeutic innovations. The event will also feature presentations by key opinion leaders: Pr. Laurence Cooper, MD Anderson Cancer Center ; Dr. Jaume Pons Senior Vice President and CSO of Rinat, the biotech unit of Pfizer and Eric Falcand, Director, Alliance Management & US Licenses at Servier Laboratories.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
Cellectis
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES